Switch theme
Sign up to access all valuation multiples
Capricor Therapeutics Inc is a clinical-stage biotechnology company focused on the development of transformative cell and exosome-based therapeutics for treating Duchenne muscular dystrophy (DMD), a rare form of muscular dystrophy which results in muscle degeneration and premature death, and other diseases with high unmet medical needs. The company's product pipeline includes CAP-1002, deramiocel an allogeneic cardiac-derived cell therapy. Deramiocel is currently advancing through Phase 3 clinical development for the treatment of Duchenne muscular dystrophy. Through its proprietary StealthXTM platform, the group uses its exosome technology to conduct preclinical research focused on vaccinology, delivering oligonucleotides, proteins, and small molecules to treat.
2005
160
LTM Revenue $36.4M
LTM EBITDA -$28.5M
$279M
Benchmark forward-looking revenue and EBITDA valuation multiples across generative AI, climate tech, semiconductors, online marketplaces, vertical SaaS and 220 more verticals.
Capricor Therapeutics has a last 12-month revenue of $36.4M and a last 12-month EBITDA of -$28.5M.
In the most recent fiscal year, Capricor Therapeutics achieved revenue of $22.3M and an EBITDA of -$41.1M.
Capricor Therapeutics expects next 12-month revenue of XXX and NTM EBITDA of XXX
See Capricor Therapeutics valuation multiples based on analyst estimates| FY 2023 | FY 2024 | FY 2025 | LTM | NTM | |
|---|---|---|---|---|---|
| Revenue | $25.2M | $22.3M | XXX | XXX | XXX |
| Gross Profit | n/a | n/a | XXX | XXX | XXX |
| Gross Margin | NaN% | NaN% | XXX | XXX | XXX |
| EBITDA | -$23.0M | -$41.1M | XXX | XXX | XXX |
| EBITDA Margin | -91% | -185% | XXX | XXX | XXX |
| Net Profit | -$29.0M | -$22.3M | XXX | XXX | XXX |
| Net Margin | -115% | -100% | XXX | XXX | XXX |
| Net Debt | n/a | n/a | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
As of April 15, 2025, Capricor Therapeutics's stock price is $9.
Capricor Therapeutics has current market cap of $429M, and EV of $279M.
See Capricor Therapeutics trading valuation data| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $279M | $429M | XXX | XXX | XXX | XXX | $-0.93 |
Sign up to access valuation multiples like growth-adjusted P/E, next 12-month EV/Revenue, EBITDA multiples by industry and many more
Sign UpAs of April 15, 2025, Capricor Therapeutics has market cap of $429M and EV of $279M.
Capricor Therapeutics's trades at 7.7x LTM EV/Revenue multiple, and -9.8x LTM EBITDA.
Analysts estimate Capricor Therapeutics's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
See valuation multiples for Capricor Therapeutics and 10K+ public comps| FY 2024 | FY 2025E | FY 2026E | FY 2027E | |
|---|---|---|---|---|
| EV | $279M | XXX | XXX | XXX |
| EV/Revenue | 12.5x | XXX | XXX | XXX |
| EV/EBITDA | -6.8x | XXX | XXX | XXX |
| P/E | -10.6x | XXX | XXX | XXX |
| P/E/Growth | n/a | XXX | XXX | XXX |
| EV/FCF | -6.7x | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2025, based on equity research analyst estimates.
Sign UpCapricor Therapeutics's NTM/LTM revenue growth is 128%
Capricor Therapeutics's revenue per employee for the last fiscal year averaged $0.1M, while opex per employee averaged $0.4M for the same period.
Over next 12 months, Capricor Therapeutics's ratio of sales and marketing spend to revenue is estimated to be XXX , while its R&D spend to revenue to be XXX .
Analysts estimate Capricor Therapeutics's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
See operational valuation multiples for Capricor Therapeutics and other 10K+ public comps| FY 2024 | NTM | FY 2025E | FY 2026E | FY 2027E | |
|---|---|---|---|---|---|
| Revenue Growth | -12% | XXX | XXX | XXX | XXX |
| EBITDA Margin | -185% | XXX | XXX | XXX | XXX |
| EBITDA Growth | 79% | XXX | XXX | XXX | XXX |
| Rule of 40 (SaaS-only) | -57% | XXX | XXX | XXX | XXX |
| Revenue per Employee | $0.1M | XXX | XXX | XXX | XXX |
| Opex per Employee | $0.4M | XXX | XXX | XXX | XXX |
| S&M Expenses to Revenue | n/a | XXX | XXX | XXX | XXX |
| G&A Expenses to Revenue | 64% | XXX | XXX | XXX | XXX |
| R&D Expenses to Revenue | 224% | XXX | XXX | XXX | XXX |
| Opex to Revenue | 291% | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Benchmark public comps and private revenue and EBITDA valuation multiples across GRC software, cloud infrastructure, DevOps, online marketplaces and so much more!
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| 2025E | 2026E | 2027E | 2025E | 2026E | 2027E | |
| Julphar | XXX | XXX | XXX | XXX | XXX | XXX |
| Benevolent AI | XXX | XXX | XXX | XXX | XXX | XXX |
| Galapagos | XXX | XXX | XXX | XXX | XXX | XXX |
| Pharming | XXX | XXX | XXX | XXX | XXX | XXX |
| Vivoryon Therapeutics | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
Capricor Therapeutics acquired XXX companies to date.
Last acquisition by Capricor Therapeutics was XXXXXXXX, XXXXX XXXXX XXXXXX . Capricor Therapeutics acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX ).
See M&A valuation multiples| Acquired Company | EV | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
Sign up to see revenue and EBITDA valuation multiples for 60K+ M&A deals.
Sign Up| When was Capricor Therapeutics founded? | Capricor Therapeutics was founded in 2005. |
| Where is Capricor Therapeutics headquartered? | Capricor Therapeutics is headquartered in United States of America. |
| How many employees does Capricor Therapeutics have? | As of today, Capricor Therapeutics has 160 employees. |
| Who is the CEO of Capricor Therapeutics? | Capricor Therapeutics's CEO is Dr. Linda Marban, PhD. |
| Is Capricor Therapeutics publicy listed? | Yes, Capricor Therapeutics is a public company listed on NAS. |
| What is the stock symbol of Capricor Therapeutics? | Capricor Therapeutics trades under CAPR ticker. |
| When did Capricor Therapeutics go public? | Capricor Therapeutics went public in 2007. |
| Who are competitors of Capricor Therapeutics? | Similar companies to Capricor Therapeutics include e.g. Julphar, Benevolent AI, Galapagos, Pharming. |
| What is the current market cap of Capricor Therapeutics? | Capricor Therapeutics's current market cap is $429M |
| What is the current revenue of Capricor Therapeutics? | Capricor Therapeutics's last 12-month revenue is $36.4M. |
| What is the current EBITDA of Capricor Therapeutics? | Capricor Therapeutics's last 12-month EBITDA is -$28.5M. |
| What is the current EV/Revenue multiple of Capricor Therapeutics? | Current revenue multiple of Capricor Therapeutics is 7.7x. |
| What is the current EV/EBITDA multiple of Capricor Therapeutics? | Current EBITDA multiple of Capricor Therapeutics is -9.8x. |
| What is the current revenue growth of Capricor Therapeutics? | Capricor Therapeutics revenue growth between 2023 and 2024 was -12%. |
| Is Capricor Therapeutics profitable? | Yes, Capricor Therapeutics is EBITDA-positive (as of the last 12 months). |
Get access to always up-to-date, precisely categorized 70K+ public and private valuation multiples, across tech and beyond.
